3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
Saved in:
| Title: | 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma. |
|---|---|
| Authors: | Chim, Chor Sang1 (AUTHOR) jcschim@hku.hk, Kumar, Shaji2 (AUTHOR), Wong, Vincent Kai Chung3 (AUTHOR), Ngai, Cheong1 (AUTHOR), Kwong, Yok Lam1 (AUTHOR) |
| Source: | Hematology. Dec 2021, Vol. 26 Issue 1, p652-655. 4p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
